Tags

Type your tag names separated by a space and hit enter

Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein.
mBio. 2020 10 20; 11(5)MBIO

Abstract

An accurate diagnostic test for early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the key weapon to control the coronavirus disease 2019 (COVID-19) pandemic. We previously reported that the SARS-CoV-2 genome contains a unique orf8 accessory gene absent from other human-pathogenic coronaviruses. Here, we characterized the SARS-CoV-2 orf8 as a novel immunogenic secreted protein and utilized it for the accurate diagnosis of COVID-19. Extracellular orf8 protein was detected in cell culture supernatant and in sera of COVID-19 patients. In addition, orf8 was found highly immunogenic in COVID-19 patients, who showed early seropositivity for anti-orf8 IgM, IgG, and IgA. We hypothesize that orf8 secretion during SARS-CoV-2 infection facilitates early mounting of B cell response. The serological test detecting anti-orf8 IgG antibody can be used for the early and accurate diagnosis of COVID-19.IMPORTANCE Current commercially available serological tests for COVID-19 patients are detecting antibodies against SARS-CoV-2 nucleoprotein and spike glycoprotein. The antinucleoprotein and antispike antibodies can be accurately detected in patients during the mid or late stage of infection, and therefore, these assays have not been widely used for early diagnosis of COVID-19. In this study, we characterized the secretory property of a SARS-CoV-2 orf8 protein and proposed that orf8 secretion during infection facilitates early mounting of the B cell response. We demonstrated the presence of anti-orf8 antibodies in both symptomatic and asymptomatic patients during the early stage of infection, while the anti-N antibody is not detected. Our serological test detecting anti-orf8 antibodies may facilitate the development of early and accurate diagnosis for COVID-19.

Links

Authors+Show Affiliations

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China.

School of Life Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China. State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China. Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong SAR, China. Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China. State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China. Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong SAR, China. Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China khkok@hku.hk kyyuen@hku.hk. State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China. Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong SAR, China. Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China.

Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China khkok@hku.hk kyyuen@hku.hk. State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China. Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong SAR, China. Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China.

MeSH

Antibodies, ViralAntigens, ViralBetacoronavirusCOVID-19Cell LineCoronavirus InfectionsEarly DiagnosisEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin GPandemicsPneumonia, ViralSARS-CoV-2Viral Proteins

Pub Type(s)

Journal Article

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33082264

Citation

Wang, Xiaohui, et al. "Accurate Diagnosis of COVID-19 By a Novel Immunogenic Secreted SARS-CoV-2 Orf8 Protein." MBio, vol. 11, no. 5, 2020.

Wang X, Lam JY, Wong WM, et al. Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein. mBio. 2020;11(5).

Wang, X., Lam, J. Y., Wong, W. M., Yuen, C. K., Cai, J. P., Au, S. W., Chan, J. F., To, K. K. W., Kok, K. H., & Yuen, K. Y. (2020). Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein. MBio, 11(5). https://doi.org/10.1128/mBio.02431-20

Wang X, et al. Accurate Diagnosis of COVID-19 By a Novel Immunogenic Secreted SARS-CoV-2 Orf8 Protein. mBio. 2020 10 20;11(5) PubMed PMID: 33082264.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein. AU - Wang,Xiaohui, AU - Lam,Joy-Yan, AU - Wong,Wan-Man, AU - Yuen,Chun-Kit, AU - Cai,Jian-Piao, AU - Au,Shannon Wing-Ngor, AU - Chan,Jasper Fuk-Woo, AU - To,Kelvin K W, AU - Kok,Kin-Hang, AU - Yuen,Kwok-Yung, Y1 - 2020/10/20/ PY - 2020/10/21/entrez PY - 2020/10/22/pubmed PY - 2020/11/5/medline KW - COVID-19 KW - SARS-CoV-2 KW - diagnosis KW - orf8 JF - mBio JO - mBio VL - 11 IS - 5 N2 - An accurate diagnostic test for early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the key weapon to control the coronavirus disease 2019 (COVID-19) pandemic. We previously reported that the SARS-CoV-2 genome contains a unique orf8 accessory gene absent from other human-pathogenic coronaviruses. Here, we characterized the SARS-CoV-2 orf8 as a novel immunogenic secreted protein and utilized it for the accurate diagnosis of COVID-19. Extracellular orf8 protein was detected in cell culture supernatant and in sera of COVID-19 patients. In addition, orf8 was found highly immunogenic in COVID-19 patients, who showed early seropositivity for anti-orf8 IgM, IgG, and IgA. We hypothesize that orf8 secretion during SARS-CoV-2 infection facilitates early mounting of B cell response. The serological test detecting anti-orf8 IgG antibody can be used for the early and accurate diagnosis of COVID-19.IMPORTANCE Current commercially available serological tests for COVID-19 patients are detecting antibodies against SARS-CoV-2 nucleoprotein and spike glycoprotein. The antinucleoprotein and antispike antibodies can be accurately detected in patients during the mid or late stage of infection, and therefore, these assays have not been widely used for early diagnosis of COVID-19. In this study, we characterized the secretory property of a SARS-CoV-2 orf8 protein and proposed that orf8 secretion during infection facilitates early mounting of the B cell response. We demonstrated the presence of anti-orf8 antibodies in both symptomatic and asymptomatic patients during the early stage of infection, while the anti-N antibody is not detected. Our serological test detecting anti-orf8 antibodies may facilitate the development of early and accurate diagnosis for COVID-19. SN - 2150-7511 UR - https://www.unboundmedicine.com/medline/citation/33082264/Accurate_Diagnosis_of_COVID_19_by_a_Novel_Immunogenic_Secreted_SARS_CoV_2_orf8_Protein_ DB - PRIME DP - Unbound Medicine ER -